Abiopharma

🔍 DeWitte Jacob (Director)

Company: Oklo Inc. (OKLO)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 16,907 shares of Class A Common Stock at $69.06 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 674,626.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 43,093 shares of Class A Common Stock at $69.83 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 631,533.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 22,063 shares of Class A Common Stock at $70.42 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 634,420.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 17,937 shares of Class A Common Stock at $70.61 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 616,483.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Sold 60,000 shares of Class A Common Stock at $70.19 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 598,039.00 | transaction_form_type: 4 | Footnotes: F1, F7, F8, F9
• Sold 40,000 shares of Class A Common Stock at $70.95 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 649,479.00 | transaction_form_type: 4 | Footnotes: F1, F10, F8, F11
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By the Jacob DeWitte Family Trust | shares_owned_after: 7,851,901.00 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By Jacob DeWitte GRAT No. 2 | shares_owned_after: 1,000,000.00 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By Jacob DeWitte GRAT No. 3 | shares_owned_after: 506,807.00 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By the Caroline DeWitte Family Trust | shares_owned_after: 7,583,085.00 | Footnotes: F8, F11
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By Caroline DeWitte GRAT No. 2 | shares_owned_after: 1,000,000.00 | Footnotes: F8, F11
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By Caroline Cochran GRAT No.3 | shares_owned_after: 474,011.00 | Footnotes: F8, F11

Footnotes:

• F1: The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted on March 31, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.50- $69.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F3: For more information about the equity of the Issuer held by the Reporting Person, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.51- $70.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.34- $70.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.52- $70.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.05- $70.34 inclusive. The Reporting Person's spouse undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F8: For more information about the equity of the Issuer held by the Reporting Person's spouse, please see the Issuer's most recent definitive proxy statement filed with the Securities and Exchange Commission.
• F9: Represents securities held by the Reporting Person's spouse.
• F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.68- $71.38 inclusive. The Reporting Person's spouse undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F11: Represents securities beneficially owned by the Reporting Person's spouse.